SCHEMBL23780820

SCHEMBL23780820

O=C(O)CC(Nc1ncnc2c1ncn2[C@H]1O[C@H](CO)[C@@H](O)[C@H]1O)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.66
ADORA2A P29274 3/20 0.66
ADORA1 P30542 2/20 0.66
SLC6A2 P23975 1/20 0.66
SLC6A3 Q01959 1/20 0.66
ALDH1A1 P00352 2/20 0.64
PMP22 Q01453 2/20 0.64
NPC1 O15118 2/20 0.64
RAB9A P51151 2/20 0.64
RXFP1 Q9HBX9 2/20 0.64
TP53 P04637 1/20 0.64
CYP3A4 P08684 1/20 0.64
TSHR P16473 1/20 0.64
ALOX12 P18054 1/20 0.64
NFKB1 P19838 1/20 0.64
HIF1A Q16665 1/20 0.64
HPGD P15428 1/20 0.64
ADORA2B P29275 1/20 0.64
LMNA P02545 2/20 0.63
GLA P06280 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15698128 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23780816 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23787290 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL20099215 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23780819 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23787289 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23780818 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL23780815 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL21631682 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3
SCHEMBL15700257 1.00 ADORA3 (0.66) ADORA3ADORA2AADORA1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210277005-A1 PROANGIOGENIC COMPOSITIONS AND METHODS OF USE UNIVERSITY OF NORTH DAKOTA 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210277005-A1 PROANGIOGENIC COMPOSITIONS AND METHODS OF USE PGF, HDGF, VEGFA ADORA3 836/4885ADORA2A 737/4885ADORA1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.